https://www.tandfonline.com/doi/full/10.1080/13102818.2020.1775118
Conclusions
The available pharmacokinetic data for ivermectin indicate that at the doses routinely used for the management of parasitic diseases the SARS-CoV-2 inhibitory concentrations are practically not attainable. At present any empiric treatment with ivermectin or its inclusion in therapeutic protocols are not scientifically justifiable. The very consideration of the drug as a broad spectrum antiviral agent is incorrect because it has failed to demonstrate antiviral effects beyond the in vitro level. Pending the paucity of reliable data from controlled studies and the aforementioned pharmacokinetic considerations, the application of ivermectin in COVID-19 patients is to be decisively discouraged.
還有，FDA這麽說的：
A: No. While there are approved uses for ivermectin in people and animals, it is not approved for the prevention or treatment of COVID-19. You should not take any medicine to treat or prevent COVID-19 unless it has been prescribed to you by your health care provider and acquired from a legitimate source.
A recently released research article described the effect of ivermectin on SARS-CoV-2 in a laboratory setting. These types of laboratory studies are commonly used at an early stage of drug development. Additional testing is needed to determine whether ivermectin might be appropriate to prevent or treat coronavirus or COVID-19. Read more about ivermectin.
